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Abstract
In the 2010 second edition of WHO’s guidelines for the treatment of malaria, the relatively new fixed dose combi-
nation dihydroartemisinin-piperaquine is included as one of the recommended artemisinin combination therapies.
However, experimental testing demonstrates that, due to its intrinsic chemical instability, dihydroartemisinin is not
suitable to be used in pharmaceutical formulations. In addition, data show that the currently available dihydroarte-
misinin preparations fail to meet the internationally accepted stability requirements. At a time when many efforts
aim to ban counterfeit and substandard drugs from the malaria market, the obvious question rises how WHO and
public-private partnerships, such as Medicine for Malaria venture (MMV), can support the production and marketing
of anti-malarial drugs that do not even meet the International Pharmacopoeia requirements?
Background
In its recent 2010 edition of recommended malaria
treatment, WHO recommends - among others - the use
of a particular fixed dose artesunate-based combination
therapy (ACT) composed of dihydroartemisinin (DHA)
and piperaquine phosphate, known under the brand
names Artekin® or Duo-cotecxin® (Holley-Cotec, China)
[1]. The prefix “duo” is used because a single-ingredient
preparation named Cotecxin, containing only DHA, had
been previously manufactured and distributed for years
in a massive manner all over Africa, strongly supported
in official relief programmes by Chinese authorities.
This product, as well as the newer Duo-cotecxin,
requires closer attention. These are the only malaria
treatments containing DHA instead of the more
commonly used artemisinin-derivatives artesunate or
artemether. Despite the fact that DHA is the most active
derivative of artemisinin, this chemical entity is a pro-
duct of major concerns from the ethical, regulatory and
therapeutics points of view.
Discussion
After the discovery in 1976 of the anti-malarial proper-
ties of artemisinin, extracted and crystallized from Arte-
misia annua leaves, it took several years before the
structure of this substance (bruto molecular structure of
C15H2205 and mol. wt. 282.35) could be elucidated
(Figure 1). X-ray crystallography indicated that this
compound had a lactone structure [2]. This led immedi-
ately to the chemical reflex of making a lactol of this
function by a selective reduction process. Such a lactol,
given the trivial name dihydroartemisinin (DHA) offers
interesting possibilities because it permits to substitute
on the molecule. Esters and ethers are the obvious deri-
vatives to be made and hence the structures of artesu-
nate and of artemether were born. It was soon found
that these substances exceeded artemisinin in intrinsic
pharmacological action against malaria parasites. DHA
received later the official generic name of artenimol.
This chemical entity is obtained after e.g. a borohydride
reduction of artemisinin in methanol at - 5°C. The reac-
tion is stopped and the DHA is precipitated with water
and acid. After washing and drying, a nearly 99% pure
DHA is obtained. DHA behaves like an amorphous
powder and has a melting point of 164°C.
Artemisinin and its derivative DHA is a fascinating
composite. Artemisinin is synthesized by the plant Arte-
misia annua, and not less than seven of its carbon
atoms are asymmetric, meaning that this molecule has
unique stereochemical features. Strictly-speaking, it is a
three cyclic ring system with a peroxide bridge build
over a seven membered heterocyclic (oxygen containing)
ring. In this ring, the peroxide function is sitting in a
configuration called a tri-oxane. In addition, the mole-
cule carries two other oxygens atoms forming a lacton
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chemistry of the molecule and each of its oxygen atoms
play an important role in its action. The presence of a
peroxide bridge on top of an oxygen containing seven
membered ring is chemically quite remarkable, and
these heterocyclic ring systems are known to be chemi-
cally rather unstable. In fact, this special ring system
interacts with the lactol function of DHA. The lactol
-OH group can exist in an alpha and beta position and
they can switch from one position to another. This flip-
flop is accompanied by ring opening of the lactol ring
system (Figure 2) [3]. This phenomenon brings extra
strain on the molecule, particularly on the seven mem-
bered ring carrying the peroxide function. When certain
conditions are met, this leads to the destruction of the
molecule. The total of processes involved in this break-
down is capable of creating a number of free radicals
which can be formed biologically. A number of such
free radicals with alkylating properties have been pre-
v i o u s l yd e s c r i b e d ,w i t hs o m en e e d i n gt h ep r e s e n c eo f
ferrous ions. The major and probably the most reactive
free radical generated by DHA is singlet oxygen when
released from the peroxide group. This singlet oxygen
can exert all the specific and non-specific reactions
linked to peroxides [4].
The chemical instability of DHA was subject of inves-
tigation by several groups. Haynes et al demonstrated
that DHA is thermally labile posing a problem, not only
in relation to product stability as defined in ICH (The
International Conference on Harmonisation of Techni-
cal Requirements for Registration of Pharmaceuticals for
Human Use) stability testing guidelines, but also because
its special physicochemical properties and relatively poor
oral bioavailability pose problems in its use in fixed
pharmaceutical formulations [5]. In addition, it was
demonstrated that DHA decomposes into several break-
down products of which two could be identified [6].
Experiments on the pure DHA raw material confirmed
the instability of this molecule and led to the suspicion
that this substance would have serious difficulties to
survive pharmaceutical legislation when used in tablets.
Pharmaceutical experiments with DHA showed that the
making of a good tablet is not an easy task and several
attempts were necessary for adequate formulation of
Figure 1 Structure of artemisinin (A), dihydroartemisinin (B), artesunate (C) and artemether (D). The insert shows the lacton (for
artemisinin) and trioxane functional groups (marked in red).
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blems were solved various types of tablets were made
that could be manufactured industrially. The problem
remained as to whether they would survive further sta-
bility testing and more particular if they would be of
sufficient quality to survive tropical climate conditions.
The critical questions were: do these tablets contain a
minimum content of active pharmaceutical ingredient
DHA at the end of shelf life? And practically, do these
tablets in their original packaging, when kept at tropical
conditions (30°C and 65-75% humidity), survive the
shelf life period of two to three years? The current inter-
national pharmaceutical law is very strict and requires a
minimum of 90% (and in some countries even 95%) API
integrity throughout the shelf-life of the product. In
addition, would breakdown products remain within the
set limits of 2 per cent?
Initially, the tablets fulfilled all criteria of hardness,
disintegration time, friability etc. However when the first
samples of PVC/aluminium blistered tablets - kept
under the conditions of stability testing - were sub-
mitted for analysis a few striking phenomena had
occurred. Nearly all blisters showed black dot incrusta-
tions in the PVC (as if it were the result of a burning)
and the tablets also showed black dot mottling. The
tablets had been stored in stability rooms (30°C/65%
relative humidity) and 40°C/75% relative humidity for
accelerated stability testing. Upon analysis the content
of DHA had fallen below 90% indicating that these
t a b l e t sw o u l dn e v e rb es u i t a b l ef o raf i n a lp r o d u c t i o n
(Table 1).
When DHA tablets were introduced on the African
market, some manufacturers established a strong posi-
tion in a number of countries and large quantities of
these drugs were donated to the population. In order to
evaluate the quality of these products, samples were
purchased in several pharmacies in Africa (before 2006)
and sent to the laboratory for quality testing. The sam-
ples were analysed using the HPLC method (related
substances, method A) described in the Monograph
Artenimol (International Pharmacopoiea, third edition,
volume 5). The results of the analyses were astonishingly
bad and none of the tablets were conform to the
requirements of the International Pharmacopoeia. In all
samples tested, the concentration of related substances
(breakdown products) was above 2%, in some samples
even above 20%. In many samples the content of DHA
had fallen to values of about 50% of the initial API con-
tent. From a medical point of view, this has serious and
negative consequences for the population at risk for
malaria. DHA tablets contain ideally 60 mg of active
ingredient and the dosing scheme in monotherapy is
such that with this low dosage it is difficult to ascertain
adequate therapy in an African population (as compared
to e.g. tablets containing 100 mg of Artesunate). In gen-
eral, the recommended dose for DHA tablets should be
significantly higher. If, however, the content of the
active ingredient in these tablets significantly drops, the
therapeutic potential of such tablets can be seriously
questioned. Even more, it could be argued that the dos-
ing given is inadequate for the treatment of malaria in
the African population. This could even be considered
as a “build-in counterfeited drug”.T h er e s u l t so ft h e s e
investigations were presented at the 2006 annual meet-
ing of the American Society of Tropical Medicine &
Hygiene [7]. Warnings about these findings were also
sent to WHO officials and to Medicines for Malaria
Venture (MMV).
After the forced withdrawal in 2006 of artemisinin-
based monotherapies for malaria under impulse of
WHO, the story of DHA and of Cotecxin could have
stopped. However, the product was replaced on the
Figure 2 Interconversion of a/b epimers of dihydroartemisinin with ring opening.
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dose combination tablet under the brand name Duo-
cotecxin. This ACT formulation was strongly supported
by MMV under a public-private partnership, in which
MMV invested many millions of dollars. In order to
know whether this new product would be fulfilling the
basic pharmaceutical requirements, a sample bought at
pharmacies in Kenya was analysed and showed again
unsatisfactory results. In fact, when subjected to stability
testing (30°C/75% relative humidity), values of 88.6% at t
= 0 months and 85.7% at t = 3 months were already
below the minimum quantity required, and the typical
side and breakdown products of DHA could be found.
A few years later, fresh samples were purchased from
Kenyan pharmacists and sent to SGS laboratories in Bel-
gium. This laboratory is internationally recognized as a
top class centre for quality and its results could not be
disputed. For the first batch tested, the active pharma-
ceutical ingredient (API) content was only 84% and
dropped to 73% at the end of shelf-life. The second
batch tested, with 99.2% API content, looked rather
reassuring. However, when the tablets were subjected to
standard accelerated stability testing (40°C and 75% rela-
tive humidity), which is a prerequisite for any tablet for-
mulation and results must comply for regulatory
purposes, already after one month the content API had
dropped to 88.6%. This is below the criterion of 90% of
API at the end of shelf life (Table 2).
Since this process was going on over the last few
years, WHO officials were informed about the instability
of DHA. They acknowledged the information and con-
firmed that a series of experts were working on these
questions (L. Rägo, personal communication). But sur-
prisingly, another joint venture was subsequently started
between MMV and the Italian company Sigma Tau to
work on the same combination. MMV was questioned
about this discrepancy and they argued that if one
started with appropriate Good Manufacturing Practice
(GMP) DHA and respected GMP rules during pharma-
ceutical manufacturing, the breakdown of DHA would
not occur (C. Hentschel, personal communication).
Unfortunately, the argument about the intrinsic
Table 1 Outcome of stability studies performed on three batches of dihydroartemisinin tablets (Dynamax, Proxi
Pharma, Belgium)
Time Assay Disintegration Dissolution Uniformity of mass Average weight Appearance
Month % Minutes %
(90-110) (≤15) (beige tablet)
Batch n° A - Accelerated stability studies: 40°C and 75% RH
Zero 97.4 conform 75 conform 0.2728 conform
1 99.3 conform 81 conform 0.2776 conform
3 80.4 conform 65 conform 0.2782 not conform
Batch n° A - Real time stability studies: 30°C and 65% RH
Zero 97.4 conform 75 conform 0.2728 conform
3 95.6 conform 70 conform 0.2769 conform
6 85.5 conform Not tested conform 0.2786 conform
Batch n° B - Accelerated stability studies: 40°C and 75% RH
Zero 91.7 conform 73 conform 0.2747 conform
1 93.9 conform 75 conform 0.2792 conform
3 77.3 conform 74 conform 0.2805 not conform
Batch n° B - Real time stability studies: 30°C and 65% RH
Zero 91.7 conform 73 conform 0.2747 conform
3 100.9 conform 67 conform 0.2775 conform
6 79.1 conform Not tested conform 0.2803 conform
Batch n° C - Accelerated stability studies: 40°C and 75% RH
Zero 93.7 conform 80 conform 0.2734 conform
1 95.0 conform 70 conform 0.2791 conform
3 88.4 conform 73 conform 0.2805 not conform
Batch n° C - Real time stability studies: 30°C and 65% RH
Zero 93.7 conform 80 conform 0.2734 conform
3 91.2 conform 68 conform 0.2785 conform
6 80.4 conform Not tested conform 0.2806 conform
Assay performed by HPLC with reference standard; appearance assessed by macroscopic inspection; disintegration, uniformity of mass and friability determined
according to European Pharmacopoea.
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Requests for receiving a sample of this high quality
GMP DHA tablets were refused at several occasions.
Solving the problem of pharmaceutical stability of
DHA would be of great importance in view of the role
these pharmaceutical formulations may have. However,
any underdosing is morbid and pharmaceutical legisla-
tion has an important role to play to safeguard the
patients. There are few examples in modern pharmaceu-
tical history that demonstrate this point more clearly.
As it stands today, the weight of evidence suggests
that none of the available pharmaceutical ACT prepara-
tions containing DHA fulfil criteria. It is remarkable
that leading journals, such as The Lancet, gave such
large volume of printing space to clinical results
obtained with an inadequate pharmaceutical preparation
[8-10]. Worse, how is it possible that WHO in its
recommendation handbook for malaria treatment pub-
lishes and recommends an inadequate drug?
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Table 2 Outcome of assay of DHA content in two batches of commercial DHA-Piperaquine tablets (Duo-cotecxin) using
method A (HPLC) as described in the International Pharmacopoeia (4
th edition)
Batch Assay
(90%-110%)
Status Storage conditions Assay
(90%-110%)
Status
171007 84.0%
(Dec ‘08)
Fail Room temperature (20°C) 73.0%
(Oct ‘09)
Fail
611008 99.2%
(T = 0)
Pass 40°C and 75% RH
(accelerated stability)
88.6%
(T = 1 month)
Fail
The date of analysis is given between brackets.
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